Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) from a strong sell rating to a sell rating in a research note issued to investors on Sunday morning,Wall Street Zen reports.

Separately, Weiss Ratings initiated coverage on Lakewood-Amedex Biotherapeutics in a report on Monday, July 20th. They set a “sell (e-)” rating for the company. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Lakewood-Amedex Biotherapeutics Price Performance

LABT opened at $1.88 on Friday. The firm’s fifty day moving average price is $2.40. The stock has a market cap of $4.46 million and a price-to-earnings ratio of -0.40. Lakewood-Amedex Biotherapeutics has a one year low of $1.66 and a one year high of $98.20.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last issued its quarterly earnings data on Friday, August 14th. The company reported ($2.75) earnings per share (EPS) for the quarter. Research analysts forecast that Lakewood-Amedex Biotherapeutics will post 4.96 earnings per share for the current year.

About Lakewood-Amedex Biotherapeutics

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.